PMID- 22587735
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121120
LR  - 20120625
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 13
IP  - 10
DP  - 2012 Jul
TI  - Combination therapy in type 2 diabetes mellitus: adding linagliptin to a stable 
      regimen of metformin and a sulfonylurea.
PG  - 1535-9
LID - 10.1517/14656566.2012.689825 [doi]
AB  - Linagliptin, the most recently approved drug of the dipeptidyl peptidase-4 
      (DPP-4) inhibitor class, is an oral agent used to improve glycemic control in 
      type 2 diabetes mellitus (T2DM). By inhibiting the DPP-4 enzyme, these drugs slow 
      the inactivation of the endogenous incretin hormones glucagon-like peptide-1 
      (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), in turn reducing 
      blood glucose levels in a glucose-dependent manner. As well as significantly 
      reducing glycosylated hemoglobin, the class has a good safety profile, with a low 
      incidence of hypoglycemia, and is not associated with weight gain. From a 
      practical point of view, they also have simple regimens, generally with 
      once-daily oral administration, and can be used as monotherapy or in combination 
      with other anti-diabetic drugs. Owens and colleagues have reported a 6-month 
      study of linagliptin add-on therapy in patients who were receiving a stable 
      regimen of metformin and a sulfonylurea, but needed additional glycemic control. 
      Linagliptin was associated with significant improvement in glycemic control and 
      was well-tolerated by patients, indicating that it provides a valuable option for 
      a large number of patients with T2DM, especially for those who would prefer to 
      add an oral therapy to a current regimen.
FAU - Aronson, Ronnie
AU  - Aronson R
AD  - LMC Diabetes & Endocrinology, Toronto, Ontario, Canada, 1929 Bayview Ave, Suite 
      106, Toronto, Ontario, M4G 3E8, Canada. Ronnie.Aronson@LMC.CA
LA  - eng
PT  - Comment
PT  - Journal Article
DEP - 20120516
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
CON - Diabet Med. 2011 Nov;28(11):1352-61. PMID: 21781152
EDAT- 2012/05/17 06:00
MHDA- 2012/05/17 06:01
CRDT- 2012/05/17 06:00
PHST- 2012/05/17 06:00 [entrez]
PHST- 2012/05/17 06:00 [pubmed]
PHST- 2012/05/17 06:01 [medline]
AID - 10.1517/14656566.2012.689825 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2012 Jul;13(10):1535-9. doi: 
      10.1517/14656566.2012.689825. Epub 2012 May 16.